{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:35:53Z","timestamp":1794926153706,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 1002 patients in the registry, 941 had\u2009\u2265\u20091 FVC and\/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior\/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.usscicomms.com\/respiratory\/IPF-PRORegistry_LungFunctionTrajectories\">https:\/\/www.usscicomms.com\/respiratory\/IPF-PRORegistry_LungFunctionTrajectories<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT01915511.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-023-02503-5","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T02:02:13Z","timestamp":1692842533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Lung function trajectories in patients with idiopathic pulmonary fibrosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Megan L","family":"Neely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S","family":"Hellkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Liesching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy R","family":"Luckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"2503_CR1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18\u2013e47.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","volume":"168","author":"HR Collard","year":"2003","unstructured":"Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538\u201342.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/rccm.200210-1245OC","volume":"168","author":"PI Latsi","year":"2003","unstructured":"Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR4","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/crj.12700","volume":"12","author":"M Doubkov\u00e1","year":"2018","unstructured":"Doubkov\u00e1 M, \u0160vancara J, Svoboda M, \u0160terclov\u00e1 M, Barto\u0161 V, Pla\u010dkov\u00e1 M, et al. EMPIRE registry, czech part: impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J. 2018;12:1526\u201335.","journal-title":"Clin Respir J"},{"key":"2503_CR5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/resp.14231","volume":"27","author":"KK Brown","year":"2022","unstructured":"Brown KK, Inoue Y, Flaherty KR, Martinez FJ, Cottin V, Bonella F, et al. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology. 2022;27:294\u2013300.","journal-title":"Respirology"},{"key":"2503_CR6","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392.","journal-title":"N Engl J Med"},{"key":"2503_CR7","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"2503_CR8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMp1500526","volume":"372","author":"BA Karimi-Shah","year":"2015","unstructured":"Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis\u2013FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372:1189\u201391.","journal-title":"N Engl J Med"},{"key":"2503_CR9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00005","volume":"142","author":"FJ Martinez","year":"2005","unstructured":"Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142:963\u20137.","journal-title":"Ann Intern Med"},{"key":"2503_CR10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","volume":"194","author":"AM Russell","year":"2016","unstructured":"Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194:989\u201397.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR12","doi-asserted-by":"crossref","first-page":"1902279","DOI":"10.1183\/13993003.02279-2019","volume":"56","author":"J Behr","year":"2020","unstructured":"Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020;56:1902279.","journal-title":"Eur Respir J"},{"key":"2503_CR13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","volume":"194","author":"B Ley","year":"2016","unstructured":"Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194:711\u201318.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR14","doi-asserted-by":"crossref","first-page":"108852","DOI":"10.1016\/j.ejrad.2020.108852","volume":"124","author":"C Romei","year":"2020","unstructured":"Romei C, Tavanti LM, Taliani A, De Liperi A, Karwoski R, Celi A, et al. Automated computed tomography analysis in the assessment of idiopathic pulmonary fibrosis severity and progression. Eur J Radiol. 2020;124:108852.","journal-title":"Eur J Radiol"},{"key":"2503_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12931-020-01524-8","volume":"21","author":"T Veit","year":"2020","unstructured":"Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P, et al. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res. 2020;21:270.","journal-title":"Respir Res"},{"key":"2503_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10928-020-09718-9","volume":"48","author":"Y Bi","year":"2021","unstructured":"Bi Y, Reki\u0107 D, Paterniti MO, Chen J, Marathe A, Chowdhury BA, et al. A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients. J Pharmacokinet Pharmacodyn. 2021;48:55\u201367.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2503_CR17","doi-asserted-by":"crossref","first-page":"e000108","DOI":"10.1136\/bmjresp-2015-000108","volume":"3","author":"EC O\u2019Brien","year":"2016","unstructured":"O\u2019Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, et al. Rationale for and design of the idiopathic pulmonary Fibrosis-PRospective outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016;3:e000108.","journal-title":"BMJ Open Respir Res"},{"key":"2503_CR18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1541-0420.2007.00954.x","volume":"64","author":"L Liu","year":"2008","unstructured":"Liu L, Huang X, O\u2019Quigley J. Analysis of longitudinal data in the presence of informative observational times and a dependent terminal event, with application to medical cost data. Biometrics. 2008;64:950\u201358.","journal-title":"Biometrics"},{"key":"2503_CR19","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324\u201343.","journal-title":"Eur Respir J"},{"key":"2503_CR21","first-page":"185","volume":"123","author":"RO Crapo","year":"1981","unstructured":"Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis. 1981;123:185\u201389.","journal-title":"Am Rev Respir Dis"},{"key":"2503_CR22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1183\/09031936.05.00034905","volume":"26","author":"N Macintyre","year":"2005","unstructured":"Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720\u201335.","journal-title":"Eur Respir J"},{"key":"2503_CR23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12890-018-0575-y","volume":"18","author":"HE Jo","year":"2018","unstructured":"Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the australian IPF registry. BMC Pulm Med. 2018;18:19.","journal-title":"BMC Pulm Med"},{"key":"2503_CR24","doi-asserted-by":"crossref","first-page":"1801130","DOI":"10.1183\/13993003.01130-2018","volume":"52","author":"G Raghu","year":"2018","unstructured":"Raghu G, Richeldi L, Crestani B, Wung P, Bejuit R, Esperet C, et al. SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). Eur Respir J. 2018;52:1801130.","journal-title":"Eur Respir J"},{"key":"2503_CR25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","volume":"20","author":"L Richeldi","year":"2020","unstructured":"Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20:3.","journal-title":"BMC Pulm Med"},{"key":"2503_CR26","doi-asserted-by":"crossref","first-page":"1902442","DOI":"10.1183\/13993003.02442-2019","volume":"57","author":"TM Maher","year":"2021","unstructured":"Maher TM, Costabel U, Glassberg MK, Kondoh Y, Ogura T, Scholand MB, et al. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021;57:1902442.","journal-title":"Eur Respir J"},{"key":"2503_CR27","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2589-7500(22)00173-X","volume":"4","author":"HP Fainberg","year":"2022","unstructured":"Fainberg HP, Oldham JM, Molyneaux PL, Allen RJ, Kraven LM, Fahy WA, et al. Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort. Lancet Digit Health. 2022;4:e862\u201372.","journal-title":"Lancet Digit Health"},{"key":"2503_CR28","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","volume":"14","author":"MO Paterniti","year":"2017","unstructured":"Paterniti MO, Bi Y, Reki\u0107 D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14:1395\u2013402.","journal-title":"Ann Am Thorac Soc"},{"key":"2503_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12931-019-1043-9","volume":"20","author":"L Snyder","year":"2019","unstructured":"Snyder L, Neely ML, Hellkamp AS, O\u2019Brien E, de Andrade J, Conoscenti CS, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019;20:105.","journal-title":"Respir Res"},{"key":"2503_CR30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12931-021-01634-x","volume":"22","author":"J Gao","year":"2021","unstructured":"Gao J, Kalafatis D, Carlson L, Pesonen IHA, Li CX, Wheelock \u00c3, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res. 2021;22:40.","journal-title":"Respir Res"},{"key":"2503_CR31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12931-021-01851-4","volume":"22","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, et al. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021;22:257.","journal-title":"Respir Res"},{"key":"2503_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12931-020-01600-z","volume":"22","author":"J Pastre","year":"2021","unstructured":"Pastre J, Barnett S, Ksovreli I, Taylor J, Brown AW, Shlobin OA, et al. Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respir Res. 2021;22:5.","journal-title":"Respir Res"},{"key":"2503_CR33","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.5858\/arpa.2011-0627-OAI","volume":"136","author":"KO Leslie","year":"2012","unstructured":"Leslie KO, Cool CD, Sporn TA, et al. Familial idiopathic interstitial pneumonia: histopathopathology and survival in 30 patients. Arch Pathol Lab Med. 2012;136:1366\u201376.","journal-title":"Arch Pathol Lab Med"},{"key":"2503_CR34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00408-021-00506-x","volume":"200","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Snyder LD, Neely ML, et al. Clinical outcomes of patients with combined idiopathic pulmonary fibrosis and emphysema in the IPF-PRO Registry. Lung. 2022;200:21\u20139.","journal-title":"Lung"},{"key":"2503_CR35","doi-asserted-by":"crossref","first-page":"2101396","DOI":"10.1183\/13993003.01396-2021","volume":"59","author":"JM Oldham","year":"2021","unstructured":"Oldham JM, Lee CT, Wu Z, et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J. 2021;59:2101396.","journal-title":"Eur Respir J"},{"key":"2503_CR36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/thoraxjnl-2011-201184","volume":"67","author":"L Richeldi","year":"2012","unstructured":"Richeldi L, Ryerson CJ, Lee JS, Bowman WS, Pugashetti JV, Dao N, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012;67:407\u201311.","journal-title":"Thorax"},{"key":"2503_CR37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","volume":"193","author":"U Costabel","year":"2016","unstructured":"Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193:178\u201385.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1378\/chest.15-0530","volume":"149","author":"ML Salisbury","year":"2016","unstructured":"Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, et al. Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline. Chest. 2016;149:491\u201398.","journal-title":"Chest"},{"key":"2503_CR39","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1183\/09031936.00165207","volume":"31","author":"MK Han","year":"2008","unstructured":"Han MK, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J, et al. Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J. 2008;31:1183\u201388.","journal-title":"Eur Respir J"},{"key":"2503_CR40","doi-asserted-by":"crossref","first-page":"e23143","DOI":"10.1097\/MD.0000000000023143","volume":"99","author":"MT Durheim","year":"2020","unstructured":"Durheim MT, Judy J, Bender S, Neely ML, Baumer D, Robinson SB, et al. A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018. Med (Baltim). 2020;99:e23143.","journal-title":"Med (Baltim)"},{"key":"2503_CR41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.chest.2020.02.009","volume":"158","author":"T Zaman","year":"2020","unstructured":"Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS. Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study. Chest. 2020;158:245\u201351.","journal-title":"Chest"},{"key":"2503_CR42","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s11739-021-02651-w","volume":"16","author":"A Caminati","year":"2021","unstructured":"Caminati A, Madotto F, Conti S, Cesana G, Mantovani L, Harari S. The natural history of idiopathic pulmonary fibrosis in a large european population: the role of age, sex and comorbidities. Intern Emerg Med. 2021;16:1793\u2013802.","journal-title":"Intern Emerg Med"},{"key":"2503_CR43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1164\/rccm.201011-1790OC","volume":"184","author":"RM du Bois","year":"2011","unstructured":"du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:459\u201366.","journal-title":"Am J Respir Crit Care Med"},{"key":"2503_CR44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1183\/09031936.00108111","volume":"39","author":"JL Hook","year":"2012","unstructured":"Hook JL, Arcasoy SM, Zemmel D, Bartels MN, Kawut SM, Lederer DJ. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J. 2012;39:359\u201365.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02503-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02503-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02503-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T19:34:18Z","timestamp":1700508858000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02503-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2503"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02503-5","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Megan L Neely, Anne S Hellkamp, Jamie L Todd and Scott M Palmer are employees of the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) to coordinate the IPF-PRO\/ILD-PRO Registry. Jamie L Todd reports grants paid to her institution from AstraZeneca and CareDx and has participated on advisory boards for Altavant Sciences, Natera, Sanofi, Theravance. Scott M Palmer reports research funding paid to DCRI from Bristol-Myers Squibb and Genentech and has participated on advisory boards for Altavant and Bristol-Myers Squibb. Shaun Bender was an employee of BIPI at the time that this study was conducted. Timothy Liesching, Justin M Oldham, Tracy R Luckhardt and Rishi Raj are principal investigators at enrolling centres for the IPF-PRO Registry. Tracy R Luckhardt serves on the IPF-PRO\/ILD-PRO Registry Biomarker Committee. Justin M Oldham serves on the IPF-PRO\/ILD-PRO Registry Publication Committee. Rishi Raj reports an investigator-initiated research grant from and has served on an advisory board for BI. Eric S White is an employee of BIPI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was approved by the relevant Institutional Review Boards and\/or local Independent Ethics Committees prior to patient enrolment at each site listed in the Acknowledgments. All patients provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"209"}}